Protagenic Therapeutics, Inc. has created a portfolio of five novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders. The most advanced of these discoveries is based on a natural peptide hormone, which plays a key role in regulating depression, anxiety and other stress-related disorders. Novel peptide targets also have applications in the areas of neuroprotection, spinal cord injuries and trauma.